3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
59
HER2-positive Breast Cancer
14
Carcinoma, Non-Small-Cell Lung
5
Breast Diseases
4
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
HER2-positive Metastatic Breast Cancer
2
Colorectal Neoplasms
2
Breast Cancer Invasive
2
Breast Cancer Female
2
Advanced Breast Cancer
2
Stomach Neoplasms
1
Solid Tumor
1
Rare Tumour
1
Rare Tumor
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
HER2+ Early or Locally Advanced Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Breast Cancer
1
HER2 Insertion Mutation Positive Advanced NSCLC
1
HER-2 Positive Colorectal Cancer
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Interventions
spartalizumab
1
sintilimab
1
pyrotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Digestive System Tumor
×
pyrotinib
×
Clear all
NCT07053150
2025-07-08
CCGLC-018
Tongji Hospital
Phase 2
Not yet recruiting
80 enrolled